Judith Cosemans

Associate professor

Dr Judith Cosemans holds a master’s degree in Biological Health Sciences with specialisation in molecular biology from Maastricht University. She became fascinated to unravel the role of platelets in arterial thrombosis during her PhD research, which focussed on the dynamic regulation of thrombus stability. After finishing her PhD in 2009, she executed an award-winning postdoc project to develop flow chamber technology as a compatible alternative for experimental animal models of arterial thrombosis.

Dr Cosemans subsequently obtained two personal grants from the Dutch Heart Foundation (2011, 2015) and a Vidi grant from the Netherlands Organisation for Scientific Research (NWO, 2016). These grants facilitate her current research line, which lies on the interface of platelet signalling and vascular biology.

Her team aims to:
• provide novel mechanistic insight into the pathophysiology of thrombosis in the heart and in the brain
• develop better diagnostic tools and novel druggable targets to prevent recurrentthrombotic events

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht

  • 2024
    • Lemmens, T. P., Bröker, V., Rijpkema, M., Hughes, C. C. W., Schurgers, L. J., & Cosemans, J. M. E. M. (2024). Fundamental considerations for designing endothelialized in vitro models of thrombosis. Thrombosis Research, 236, 179-190. https://doi.org/10.1016/j.thromres.2024.03.004
  • 2023
    • Yakusheva, A., Slater, A., Payrastre, B., Garcia, C., D'Italia, G., Allan, H., Cosemans, J. M. E. M., Harper, M., Gawaz, M., Armstrong, P., Troitiño, S., Trivigno, S. M. G., Naik, U. P., & Senis, Y. A. (2023). Illustrated Abstracts of the 5th EUPLAN International Conference. Research and practice in thrombosis and haemostasis, 7(7), Article 102140. https://doi.org/10.1016/j.rpth.2023.102140
    • Schönichen, C., Montague, S. J., Brouns, S. L. N., Burston, J. J., Cosemans, J. M. E. M., Jurk, K., Kehrel, B. E., Koenen, R. R., Ní Áinle, F., O'Donnell, V. B., Soehnlein, O., Watson, S. P., Kuijpers, M. J. E., Heemskerk, J. W. M., & Nagy, M. (2023). Antagonistic Roles of Human Platelet Integrin aIIbβ3 and Chemokines in Regulating Neutrophil Activation and Fate on Arterial Thrombi Under Flow. Arteriosclerosis Thrombosis and Vascular Biology, 43(9), 1700-1712. https://doi.org/10.1161/ATVBAHA.122.318767
    • Josefsson, E. C., Ramstrom, S., Thaler, J., Lordkipanidze, M., Cosemans, J., & COAGAPO Study Group (2023). Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH. Journal of Thrombosis and Haemostasis, 21(8), 2291-2299. https://doi.org/10.1016/j.jtha.2023.05.001
  • 2022
    • Karel, M. F. A., Roosen, M. G. C. H., Tullemans, B. M. E., Zhang, C. E., Staals, J., Cosemans, J. M. E. M., & Koenen, R. R. (2022). Characterization of cerebral small vessel disease by neutrophil and platelet activation markers using artificial intelligence. Journal of Neuroimmunology, 367, Article 577863. https://doi.org/10.1016/j.jneuroim.2022.577863
    • Lemmens, T. P., Coenen, D. M., Swieringa, F., Niessen, I. C. L., Coort, S. L. M., Koenen, R. R., Kutmon, M., & Cosemans, J. M. E. M. (2022). Finding the "switch" in platelet activation: prediction of key mediators involved in reversal of platelet activation using a novel network biology approach. Journal of Proteomics, 261, Article 104577. https://doi.org/10.1016/j.jprot.2022.104577
    • Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80]. Thrombosis Research, 213, 113-113. https://doi.org/10.1016/j.thromres.2022.03.012
    • Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thrombosis Research, 212, 72-80. https://doi.org/10.1016/j.thromres.2022.02.020
    • Cosemans, J. M. E. M. (2022). Platelet-derived MMP-2 in the prevention of plaque formation: how many strokes is par?European Heart Journal, 43(6), 515–517. https://doi.org/10.1093/eurheartj/ehab665
    • Karel, M. F. A., Lemmens, T. P., Tullemans, B. M. E., Wielders, S. J. H., Gubbins, E., van Beurden, D., van Rijt, S., & Cosemans, J. M. E. M. (2022). Characterization of Atherosclerotic Plaque Coating for Thrombosis Microfluidics Assays. Cellular and Molecular Bioengineering, 15(1), 55-65. https://doi.org/10.1007/s12195-021-00713-9